Chrono Therapeutics, Inc., based in Hayward, California, is developing a novel smoking cessation therapy - the first wearable transdermal drug delivery device that optimises drug dosing through digitalised timed delivery. Chrono's solution revolutionises how people quit the addiction through medication timed to their cravings and with the addition of proactive, real-time coaching just when help is needed the most.
Smoking is highly addictive and remains one of the world’s great killers. According to the World Health Organization (“WHO”), around 6m people die prematurely from tobacco-related diseases each year, and this number could rise to more than 8m by 2030. Research shows that nicotine may be as addictive as heroin, cocaine or alcohol, and most smokers try to quit between 8-10 times.
1. Alan Levy, Ph.D (Chairman & CEO)
Dr. Levy brings more than 30 years of senior operational leadership and experience in the medical device industry. He was the founding CEO of Incline Therapeutics that was acquired by The Medicines Company in January 2013 for up to USD 390m. Previously, he was the President and CEO of Northstar Neuroscience, a company developing innovative therapies for neurological diseases and disorders. Dr. Levy also served as the CEO of Heartstream, Inc. and was the President of Heart Technology, Inc.
Dr. Levy received his Ph.D. in Organic Chemistry from Purdue University, a B.S. in Chemistry from City University of New York, and holds an Honorary Doctor of Science from Purdue University. He serves as a board member of several public and private companies including Intuitive Surgical, Proteus Digital Health and Seattle BioMed.
2. Tony Rimac (CFO)
Mr. Rimac joins Chrono from Aldea Pharmaceuticals where he was Chief Financial Officer. Prior to Aldea, Tony served as CFO of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), a neurology focused company and Aerovance, Inc., a privately held biopharmaceutical company, spun off from Bayer Pharmaceuticals in 2004, focused on development and commercialisation of clinical-stage products for respiratory and allergic diseases. Tony has over 25 years of broad operating and finance experience including 18 years in the life sciences industry ranging from biotech, specialty pharmaceuticals, drug delivery and medical devices and has raised in excess of USD 400m in equity and debt capital and partnership financing.
Tony received an MBA from Santa Clara University’s Graduate School of Business Administration, and a B.A. in Business Economic – Accounting Emphasis from the University of California at Santa Barbara. Tony is also a licensed Certified Public Accountant in the State of California (inactive).
3. Patti Oto, R.Ph. (SVP of Regulatory Affairs and Quality Assurance)
Patti Oto has over 25 years of executive leadership experience with regulatory and quality oversight. Prior to joining Chrono Therapeutics, Patti was at Incline Therapeutics (acquired by The Medicines Company) where she served as the Vice President of Global Regulatory and Quality, managing the regulatory and quality activities for the analgesia pipeline. Previous to Incline, Patti worked in roles of increasing responsibilities in quality and regulatory at Onyx Pharmaceuticals (Amgen), Corgentech (Anesiva), Coulter (Corixa, GlaxoSmithKline), Genentech (Roche), and Syntex. Patti has worked on global regulatory submissions in support of marketing authorisations for biologics, drugs and drug/device combination products in several therapeutic areas including cardiovascular, metabolics, oncology and pain management.
Patti is a registered pharmacist and received her B.S. in Pharmacy from the University of New Mexico.
4. Patrick H. Ruane, Ph.D. (SVP of Research & Development)
Dr. Ruane has nearly 2 decades of experience in drug delivery for combination medical devices. He most recently served as Vice President of R&D at CV Ingenuity (acquired by Covidien) and has held various positions in R&D at Xtent Inc., Cook Group and Navigant Biotechnologies.
Dr. Ruane received his primary degrees in Chemistry from The Galway-Mayo Institute of Technology and Trinity College Dublin, his Ph.D. from University College Dublin and Post-Docs at University of Toronto and The Johns Hopkins University. He is published extensively in both the academic and patent literature.
5. Guy DiPierro (Founder and VP of Government Affairs & Intellectual Property)
Mr. DiPierro has been involved in the creation of new technology for several years and is the inventor of 7 granted U.S. patents, 10 OUS patents and multiple pending applications. He previously served as Executive Vice President and General Counsel of AMGI Capital. Prior to that, he was a corporate M&A and technology licensing attorney at both Sidley Austin and Hogan and Hartson where he represented Columbia University to create, incubate and fund companies based on new technologies developed at the institution.
Mr. DiPierro has a B.S. in Accounting from State University of New York at Albany, Summa Cum Laude, and a Juris Doctor from Fordham University where he sat on the Law Review Journal.